XSHG
600993
Market cap1.46bUSD
Oct 09, Last price
22.95CNY
1D
1.32%
1Q
-1.29%
Jan 2017
14.92%
IPO
880.77%
Name
Mayinglong Pharmaceutical Group Co Ltd
Chart & performance
P/E
17.01
P/S
2.56
EPS
1.35
Div yield, %
2.74%
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
6.73%
Revenues
3.87b
+3.72%
Net income
581m
+10.11%
CFO
600m
+20.67%
Dividend
Aug 05, 20260.7 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mayinglong Pharmaceutical Group Co., LTD. is a prominent Chinese entity primarily engaged in the manufacturing, wholesale, and retail of a diverse array of pharmaceutical products. Its extensive offerings encompass treatments for hemorrhoid, gynecological, cough, and skin conditions, alongside functional foods, traditional Chinese medicine drink tablets, and various medical devices. The company also facilitates sales through online channels. Expanding its operations, it additionally manages and runs its own hospitals. Headquartered in Wuhan, China, Mayinglong Pharmaceutical Group Co., LTD. possesses a rich history, having been founded in 1582.
Key people
Ping Chen
Chairman of the Board · since 1995
Guangxiang Su
Vice Chairman of the Board · since 2019
Tao Mao
Chief Financial Officer · since 2023
Pingan Liu
Deputy General Manager · since 2021
Zhiqi Song
Deputy General Manager
Zhengjun Tian
Deputy General Manager · since 2019
Yu Bai
Assistant General Manager
Wei Zhang
Assistant General Manager
Daonian Zhou
Assistant General Manager
Qian Ma
Secretary of the Board, Assistant General Manager · since 2019
Kuangguo Chen
Director
Lei Jia
Director · since 2024
Youzhang Xia
General Manager, Director · since 2019
Shixu You
Director · since 2019
Caomin Zhai
Director
Yanhua Huang
Independent Director
Peng Mao
Independent Director
Zhinan Mei
Independent Director · since 2024
Jun Qi
Independent Director · since 2022
Man Zhao
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||